Get the App

Back Stocks profile

Stock analysis tool for investors

Aarti Drugs Ltd.

NSE: AARTIDRUGS | BSE:524348

₹490.00 4.85 (1.00%) 1D

Pharmaceuticals & Biotechnology

Buy Sell
View detailed Technical chart

Open an Account with Bigul in 5 minutes

Performance

Today’s low

483.00

Today’s High

491.00

52W low

431.00

52W High

645.80

Open Price

487.50

Prev. Close

548.40

Volume

70167.00

Value

34381830.00

Fundamentals

Market Cap Cr

4504.80

Price to Earnings

26.30

Price to Book Value

3.50

Dividend Yield

0.20

PE to Growth

8.60

Op Revenue TTM Cr

2528.58

Net Profit TTM Cr

171.42

Cash From Operating Activity Cr

358.92

Return on Equity %

13.38

EMA & SMA

Bullish Moving Averages

11

Bearish Moving Averages

5

5Day EMA

478.4

10Day EMA

479.7

12Day EMA

480.7

20Day EMA

483.1

26Day EMA

483.9

50Day EMA

487.1

100Day EMA

492.9

200Day EMA

494

5Day SMA

474.6

10Day SMA

477.4

20Day SMA

488.6

30Day SMA

489.8

50Day SMA

479

100Day SMA

498.9

150Day SMA

495.5

200Day SMA

514.7

DELIVERY AND VOLUME

DAILY AVG. DELIVERY VOLUME %

16 May, 2024

50.3

Week

41.2

Month

41.7

LEGEND

Positive Indicator

Neutral Indicator

Negative Indicator

RESISTANCE AND SUPPORT

482.87

PIVOT

First Resistance

488.23

Second Resistance

491.32

Third Resistance

496.68

First Support

479.78

Second Support

474.42

Third Support

471.33

Relative Strength Index

50.64

Money Flow Index

36.15

MACD

-3.27

MACD Signal

-1.57

Average True Range

13.35

Average Directional Index

18.61

Rate of Change (21)

-1.11

Rate of Change (125)

-0.37

Commodity Channel Index

-34.7

Williams %R

-50

BETA

1 Month

1.08

3 Month

1.33

1 Year

0.59

3 Year

0.38

PRICE CHANGE ANALYSIS

↑ 7.15%

1 Week

Low

High

456

490.95

↓ -0.96%

1 Month

Low

High

456

514.3

↓ -7.54%

3 Months

Low

High

431.05

568

↑ 3.45%

6 Months

Low

High

431.05

568

↑ 6.87%

1 Year

Low

High

431.05

645.75

Indicator Mar 2024 Dec 2023 Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022 Dec 2021 Sep 2021 Graph
Total Qtr Revenue cr 560.64 539.89 578.28 592.29 697.34 626.50 624.92 551.44 642.10 594.83 511.59
Operating Expenses Qtr 490.47 478.47 512.12 519.73 607.89 556.55 554.65 496.47 557.38 502.53 441.56
Operating Profit Qtr 69.06 59.74 65.42 71.90 88.52 68.98 70.18 54.73 84.10 90.68 69.14
EBIDT Qtr Cr 70.17 61.42 66.16 72.56 89.45 69.95 70.27 54.97 84.72 92.30 70.03
Depreciation Qtr 12.34 11.80 11.78 11.75 11.68 11.87 11.92 11.83 11.88 11.95 11.81
Net Profit Qtr 36.14 31.62 34.58 39.54 53.17 36.71 36.58 26.35 53.00 55.85 40.61
Basic EPS Qtr 3.93 3.44 3.75 4.27 5.74 3.96 3.95 2.85 5.72 6.03 4.39
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Total Revenue Annual 2271.09 2500.20 2255.95 1921.31 1635.98
Operating Expenses Annual Cr 2000.78 2215.57 1932.99 1513.62 1390.51
Operating Profit Annual 266.13 282.40 318.18 401.27 244.41
Operating Profit Margin Annual % 11.72 11.30 14.10 20.89 14.94
Total Expenses Annual Cr 2078.61 2295.39 2000.45 1583.83 1469.39
EBIDT Annual Cr 270.31 284.64 322.96 407.69 245.47
EBIDT Annual margin % 11.90 11.38 14.32 21.22 15.00
Depreciation 47.67 47.29 47.39 47.60 46.67
PAT Before ExtraOrdinary Items Annual Cr 141.88 152.81 195.00 257.71 135.67
Net Profit Annual 141.88 152.81 195.00 257.71 135.67
Basic EPS Annual 15.35 16.50 21.04 27.65 58.12
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Total ShareHolders Funds Annual 1175.21 1114.30 972.17 859.61 621.79
Minority Interest Liability Annual Cr - - - - -
Total Non Current Liabilities Annual Cr 311.81 250.20 207.67 255.50 292.91
Total Current Liabilities Annual Cr 684.60 830.99 854.68 521.89 555.99
Total Capital Plus Liabilities Annual Cr 2171.62 2195.50 2034.52 1637.01 1470.70
Fixed Assets Annual 942.16 795.23 709.03 646.47 622.53
Total Non Current Assets Annual 990.60 845.96 761.33 676.88 645.33
Total Current Assets Annual 1181.02 1349.53 1273.19 960.13 825.36
Total Assets Annual 2171.62 2195.50 2034.52 1637.01 1470.70
Contingent Liabilities plus Commitments Annual Cr - 258.17 194.24 152.85 89.82
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Cash from Operating Activity Annual 337.10 162.28 39.90 154.08 196.15
Cash from Investing Activity Annual -187.09 -131.14 -125.36 -68.93 -29.35
Cash from Financing Annual Activity -148.81 -30.54 84.11 -85.28 -167.76
Net Cash Flow Annual - 0.61 -1.35 -0.13 -0.96
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Book Value Per Share Annual 127.82 120.33 104.99 92.23 266.86
ROE Annual % 12.07 13.71 20.05 29.98 21.82
ROCE Annual % 14.97 17.39 23.35 32.29 21.73
Total Debt to Total Equity Annual 0.40 0.48 0.53 0.34 0.53
EBDIT Annual Margin % 11.92 11.39 14.34 21.29 15.01
Indicator Mar 2024 Dec 2023 Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022 Dec 2021 Sep 2021 Graph
Total Qtr Revenue cr 621.07 607.61 642.23 661.71 743.28 664.97 687.77 622.22 697.23 641.46 579.70
Operating Expenses Qtr 534.18 535.80 565.10 577.03 648.87 593.31 613.45 554.82 608.27 544.80 505.88
Operating Profit Qtr 85.81 70.14 76.44 84.08 93.54 70.65 74.27 67.14 86.00 90.00 73.74
EBIDT Qtr Cr 86.89 71.81 77.13 84.68 94.41 71.66 74.32 67.40 88.96 96.66 73.82
Depreciation Qtr 13.58 12.66 12.61 12.60 12.50 12.62 12.66 12.54 12.55 12.60 12.48
Net Profit Qtr 47.31 36.67 39.59 47.85 56.09 36.68 38.75 34.79 55.32 58.28 42.58
Basic EPS Qtr 5.15 3.99 4.29 5.18 6.07 3.96 4.18 3.76 5.97 6.29 4.60
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Total Revenue Annual 2532.61 2718.25 2499.96 2159.30 1807.57
Operating Expenses Annual Cr 2212.11 2410.45 2159.21 1717.67 1544.27
Operating Profit Annual 316.47 305.61 329.44 437.10 261.82
Operating Profit Margin Annual % 12.50 11.24 13.18 20.24 14.48
Total Expenses Annual Cr 2297.08 2494.07 2230.01 1790.52 1626.75
EBIDT Annual Cr 320.50 307.80 340.75 441.63 263.30
EBIDT Annual margin % 12.65 11.32 13.63 20.45 14.57
Depreciation 51.45 50.32 50.05 49.88 48.75
PAT Before ExtraOrdinary Items Annual Cr 171.59 166.36 205.00 280.40 141.40
Net Profit Annual 171.59 166.31 205.04 280.41 141.40
Basic EPS Annual 18.56 17.97 22.12 30.09 60.57
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Total ShareHolders Funds Annual 1281.55 1192.43 1036.36 913.42 652.49
Minority Interest Liability Annual Cr 0.41 0.23 -0.06 -0.02 -0.00
Total Non Current Liabilities Annual Cr 354.86 295.75 231.60 257.25 299.31
Total Current Liabilities Annual Cr 795.54 932.98 940.06 595.36 624.70
Total Capital Plus Liabilities Annual Cr 2432.36 2421.40 2207.96 1766.01 1576.50
Fixed Assets Annual 1070.22 886.58 766.67 684.66 656.02
Total Non Current Assets Annual 1111.64 929.05 814.59 709.22 672.50
Total Current Assets Annual 1320.72 1492.35 1393.37 1056.80 904.00
Total Assets Annual 2432.36 2421.40 2207.96 1766.01 1576.50
Contingent Liabilities plus Commitments Annual Cr - 262.94 211.49 155.67 92.06
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Cash from Operating Activity Annual 358.92 134.20 69.64 154.85 250.74
Cash from Investing Activity Annual -223.65 -163.97 -148.86 -71.68 -33.21
Cash from Financing Annual Activity -136.03 16.54 92.03 -81.13 -215.41
Net Cash Flow Annual - -13.23 12.80 2.04 2.13
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Book Value Per Share Annual 139.43 128.80 111.91 98.00 280.04
ROE Annual % 13.38 13.94 19.78 30.69 21.67
ROCE Annual % 16.43 17.29 22.92 33.46 22.54
Total Debt to Total Equity Annual 0.44 0.51 0.52 0.33 0.52
EBDIT Annual Margin % 12.67 11.33 13.69 20.49 14.57
Name Holding Percent Holding Id Pledged % Locked %
Name Holding Percent Holding Id Pledged % Locked %
Prakash Moreshwar Patil 9.24 75061479 0 0
Harshit Manilal Savla 4.74 75061480 0 0
Rashesh Chandrakant Gogri 4.65 75061481 0 0
Priti Prakash Patil 4.4 75061482 0 0
Seema Harshit Savla 3.84 75061483 0 0
Hetal Gogri Gala 3.06 75061484 0 0
Chandrakant Vallabhaji Gogri 1.87 75061485 0 0
Jaya Chandrakant Gogri 1.71 75061486 0 0
Mirik Rajendra Gogri 1.31 75061487 0 0
Renil Rajendra Gogri 1.25 75061488 0 0
Adhish P. Patil 1.24 75061489 0 0
Bhoomi Harshit Savla 1.09 75061490 0 0
Vishwa Harshit Savla 1.03 75061491 0 0
Aashay Rashesh Gogri 0.96 75061492 0 0
Rajendra Vallabhaji Gogri 0.52 75061493 0 0
Gogri Finserv Pvt. Ltd. 3.8 75061510 0 0
Anushakti Enterprise Private Limited 2.62 75061511 0 0
Alchemie Finserv Pvt. Ltd. 2.21 75061512 0 0
Aashyav Business Trust (Alabhya Trusteeship Private Limited) 1.5 75061513 0 0
Tulip Family Trust (Gloire Trusteeship Services Private Limited) 1.01 75061514 0 0
Orchid Family Trust (Relacion Trusteeship Services Private Limited) 0.99 75061515 0 0
Paridhi Business Trust (Saswat Trusteeship Private Limited) 0.64 75061516 0 0
Safechem Enterprises Private Limited 0.61 75061517 0 0
Dilesh Roadlines Pvt Ltd 0.54 75061518 0 0
Name Holding Percent Holding Id
DSP Small Cap Fund 5.02 75061524
Name Holding Percent Holding Id
Nikhil Parimal Desai 1.12 75061540
HUF 0.69 75061532
Harit Pragji Shah 2.67 75061544
Jayshree Harit Shah 1.79 75061545
Ex-Date Dividend Amount Dividend Type Record Date Instrument Type
Feb 06, 2024 1 INTERIM Feb 06, 2024 Equity Share
Feb 08, 2023 1 INTERIM Feb 08, 2023 Equity Share
Feb 09, 2022 1 INTERIM Feb 10, 2022 Equity Share
Nov 03, 2020 2.5 INTERIM Nov 04, 2020 Equity Share
Feb 17, 2020 2 INTERIM Feb 18, 2020 Equity Share
Jul 26, 2019 1 FINAL - Equity Share
Aug 01, 2018 1 FINAL - Equity Share
Aug 09, 2017 1 FINAL - Equity Share
Mar 22, 2016 3 INTERIM Mar 24, 2016 Equity Share
Feb 12, 2016 1.5 INTERIM Feb 15, 2016 Equity Share
Nov 10, 2015 2.25 INTERIM Nov 14, 2015 Equity Share
Aug 05, 2015 3 FINAL - Equity Share
Feb 04, 2015 5 INTERIM Feb 05, 2015 Equity Share
Nov 19, 2014 5 INTERIM Nov 20, 2014 Equity Share
Jul 02, 2014 5.5 FINAL - Equity Share
Feb 05, 2014 4.5 INTERIM Feb 06, 2014 Equity Share
Nov 19, 2013 3 INTERIM Nov 20, 2013 Equity Share
Jul 24, 2013 4 FINAL - Equity Share
Feb 11, 2013 3 INTERIM Feb 12, 2013 Equity Share
Nov 05, 2012 3 INTERIM Nov 06, 2012 Equity Share
Aug 17, 2012 3 FINAL - Equity Share
Feb 06, 2012 2 INTERIM Feb 07, 2012 Equity Share
Jul 14, 2011 2.5 FINAL - Equity Share
Feb 07, 2011 2.5 INTERIM Feb 08, 2011 Equity Share
Aug 18, 2010 5 FINAL - Equity Share
Jul 23, 2009 3 FINAL - Equity Share
Aug 13, 2008 1.8 FINAL - Equity Share
Mar 20, 2007 1.2 INTERIM Mar 21, 2007 Equity Share
Jul 19, 2006 1.5 FINAL - Equity Share
Jul 27, 2005 1.6 FINAL - Equity Share
Nov 04, 2004 1.4 INTERIM Nov 06, 2004 Equity Share
Jun 25, 2004 1.8 FINAL - Equity Share
Nov 13, 2003 1.2 INTERIM Nov 15, 2003 Equity Share
Jul 25, 2003 1.5 FINAL - Equity Share
Jun 20, 2002 - FINAL - Equity Share
Oct 23, 2001 - INTERIM Nov 08, 2001 Equity Share
Jun 11, 2001 - FINAL - Equity Share
Ex-Date Split Ratio Record Date
Ex-Date Purpose Notes
May 03, 2024 Audited Results -
Jan 24, 2024 Quarterly Results & Interim Dividend -
Oct 19, 2023 Quarterly Results -
Jul 21, 2023 Quarterly Results & Buy Back -
Apr 29, 2023 Audited Results -
Jan 27, 2023 Quarterly Results & Interim Dividend -
Oct 20, 2022 Quarterly Results -
Jul 27, 2022 Quarterly Results -
May 09, 2022 Audited Results -
Jan 31, 2022 Audited Results & Interim Dividend -
Oct 27, 2021 Quarterly Results -
Jul 27, 2021 Quarterly Results -
May 15, 2021 Audited Results -
Mar 19, 2021 Buy Back of Shares -
Jan 25, 2021 Quarterly Results -
Oct 23, 2020 Audited Results -
Oct 20, 2020 Audited Results & Interim Dividend -
Aug 20, 2020 Bonus issue -
Jul 25, 2020 Quarterly Results -
May 15, 2020 Audited Results -
Feb 06, 2020 Quarterly Results & Interim Dividend -
Oct 23, 2019 Audited Results -
Jul 26, 2019 Quarterly Results -
May 15, 2019 Audited Results & Final Dividend -
Mar 15, 2019 Buy Back of Shares -
Feb 11, 2019 Quarterly Results -
Nov 02, 2018 Quarterly Results -
Aug 13, 2018 Quarterly Results -
May 16, 2018 Audited Results & Final Dividend -
Feb 13, 2018 Quarterly Results -
Jan 08, 2018 Buy Back of Shares -
Nov 13, 2017 Quarterly Results -
Aug 18, 2017 Quarterly Results -
May 23, 2017 Audited Results & Final Dividend -
Feb 08, 2017 Quarterly Results -
Nov 09, 2016 Quarterly Results -
Oct 17, 2016 Buy Back of Shares -
Aug 12, 2016 Quarterly Results -
May 05, 2016 Audited Results -
Mar 16, 2016 3rd Interim Dividend -
Feb 05, 2016 Quarterly Results & 2nd Interim Dividend -
Nov 06, 2015 Quarterly Results & Interim Dividend -
Jul 31, 2015 Quarterly Results -
May 20, 2015 Audited Results & Final Dividend -
Mar 26, 2015 Others To consider & approve the allotment of 121,08,550 Equity shares as Bonus issue in the proportion of 1 new equity share for every 1 (One) existing fully paid equity shares.
Jan 30, 2015 Quarterly Results & Interim Dividend Second Interim Dividend
Nov 14, 2014 Quarterly Results & Interim Dividend -
Aug 08, 2014 Quarterly Results -
Apr 30, 2014 Audited Results & Final Dividend -
Jan 31, 2014 Quarterly Results & 2nd Interim Dividend -
Nov 14, 2013 Quarterly Results & Interim Dividend -
Aug 02, 2013 Quarterly Results -
May 16, 2013 Audited Results & Final Dividend -
Feb 06, 2013 Quarterly Results & Interim Dividend -
Oct 31, 2012 Quarterly Results & Interim Dividend -
Aug 10, 2012 Quarterly Results -
Jul 09, 2012 Audited Results Inter alia, to reconsider, approve and take on record the Audited Financial Results for the year ended March 31, 2012, post amalgamation of Suyash Laboratories Ltd. with the Company.
May 25, 2012 Audited Results & Final Dividend -
Feb 09, 2012 Others The Board has consider the Sucession Plan post retirement of Shri. Chandrakant V Gogri as the Chairman of the Company w.e.f August 16, 2012 on his attaining the age of 66 years.
Feb 01, 2012 Quarterly Results & Interim Dividend -
Nov 11, 2011 Quarterly Results -
Jul 29, 2011 Quarterly Results -
May 25, 2011 Audited Results & Final Dividend -
Feb 02, 2011 Quarterly Results & Interim Dividend -
Oct 29, 2010 Quarterly Results -
Jul 30, 2010 Quarterly Results -
May 26, 2010 Audited Results & Dividend -
Jan 25, 2010 Quarterly Results -
Dec 20, 2009 Allotment of Equity Shares The Board has allotted 4,00,000 Equity Shares of Rs. 10/- each fully paid up against exercise of option of Conversion by the holders of Conv. Warrants issued by the Company on preferential basis.
Oct 30, 2009 Quarterly Results -
Jul 30, 2009 Quarterly Results -
May 20, 2009 Audited Results & Dividend -
Jan 29, 2009 Quarterly Results (Revised)
Oct 20, 2008 Quarterly Results -
Aug 06, 2008 To call an EGM & Others To consider: Allotment of one Equity share of Rs 10/- each & to determine "Relevant Date" for the purpose said issue price for the Preferential Issue of the warrants.
Jul 28, 2008 Quarterly Results -
May 13, 2008 Audited Results & Final Dividend -
Jan 28, 2008 Quarterly Results -
Oct 30, 2007 Quarterly Results -
Jul 30, 2007 Quarterly Results -
May 18, 2007 Audited Results & Final Dividend Has not recommended any final dividend.
Mar 12, 2007 Interim Dividend -
Jan 22, 2007 Quarterly Results -
Oct 19, 2006 Quarterly Results -
Jul 31, 2006 Quarterly Results -
May 10, 2006 Accounts & Dividend -
Jan 27, 2006 Quarterly Results -
Nov 08, 2005 Quarterly Results & Half Yearly Results -
Jul 29, 2005 Quarterly Results & Accounts (Revised)
May 05, 2005 Others Board has decided to acquire controlling stake in Suyash Laboratories Ltd (Suyash) thereby making it 51% subsidiary of the Company subject to necessary approvals from appropriate authority.
Apr 25, 2005 Accounts, Qtr Results & F. Dividend -
Apr 08, 2005 Allotment of Unsecured FCCB's Board has allotted 12750 Unsecured Foreign Currency Convertible Bonds (FCCBs) of US$ 1000 each aggregating to US$ 12,750,000 (US Dollar Twelve Million Seven Hundred Fifty Thousand Only).
Jan 21, 2005 Quarterly Results -
Dec 31, 2004 To issue securities like FCCB's Proposal to issue/offer securities like Foreign Currency Convertible Bonds (FCCB) and/or Equity Shares (through Depository Receipt Mechanism) and/or Fully Convertible Debentures.
Oct 29, 2004 Quarterly Results -
Jul 28, 2004 Accounts -
Apr 23, 2004 Accounts & Final Dividend -
Jan 21, 2004 Quarterly Results -
Oct 31, 2003 Interim Dividend & Quarterly Results (Revised)
Jul 21, 2003 Quarterly Results -
Apr 23, 2003 Final Dividend & Accounts -
Jan 20, 2003 Quarterly Results -
Oct 28, 2002 Accounts & Buy Back of Shares -
Jul 19, 2002 Quarterly Results -
May 10, 2002 Final Dividend -
Apr 17, 2002 Dividend & Quarterly Results -
Mar 09, 2002 Interim Dividend (Cancelled)
Jan 18, 2002 Quarterly Results -
Oct 31, 2001 Interim Dividend & Half Yearly Results -
Jul 18, 2001 Quarterly Results -
Apr 18, 2001 Accounts & Dividend Dividend announced on 11/04/2001
Jan 22, 2001 Quarterly Results -
Oct 18, 2000 Quarterly Results -
Apr 18, 2000 Accounts -
Mar 28, 2000 2nd Interim Dividend -
Jan 28, 2000 Quarterly Results -
Oct 27, 1999 Quarterly Results -
Jul 30, 1999 Quarterly Results -
Apr 29, 1999 Quarterly Results -
Jan 29, 1999 Quarterly Results -
Jan 22, 1999 Revised -
Jan 20, 1999 Quarterly Results -
Oct 30, 1998 Quarterly Results -
Jul 20, 1998 Quaterly Results -
May 05, 1998 Accounts & Dividend -
Nov 26, 1997 Half Yearly Results -
Ex-Date Bonus Ratio Record Date
Sep 30, 2020 3:1 2020-10-01
Mar 24, 2015 1:1 2015-03-25
Bigul
15 May 2024

AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Newspaper Publication of Postal Ballot Notice
Bigul
14 May 2024

AARTI DRUGS LTD. - 524348 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Intimation of issue of duplicate share certificate
Bigul
14 May 2024

AARTI DRUGS LTD. - 524348 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

 Postal Ballot Notice
Bigul
10 May 2024

AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

 Q4 FY 24 earning call transcript.
Bigul
08 May 2024

AARTI DRUGS LTD. - 524348 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Intimation of Loss of share certificate.
07 May 2024

Aarti Drugs Q4 Results Review - API Prices Bottomed Out: Axis Securities

 In the API sector, a positive shift in the export landscape is anticipated in the near future, supported by interest rate reductions, low stock levels, and an upswing in demand.
Bigul
06 May 2024

AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

 Recording of Conference Call
Bigul
06 May 2024

Q4FY24 Quarterly & FY24 Annual Result Announced for Aarti Drugs Ltd.

 Pharmaceuticals company Aarti Drugs announced consolidated Q4FY24 & FY24 results: Q4FY24 Financial Highlights: Revenue stood at Rs 621.1 crore as against Rs 743.3 crore, a decline of 16.4% YoY EBITDA stood at Rs 86.9 crore as against Rs 94.4 crore YoY. EBITDA Margin (%) came in at 14.0% PAT stood at Rs 47.3 crore as against Rs 56.2 crore YoY. PAT Margin (%) stood at 7.6% FY24 Financial Highlights: Revenue stood at Rs 2,532.6 crore as against Rs 2,718.2 crore, a decline of 6.8% YoY EBITDA stood at Rs 320.5 crore as against Rs 307.8 crore YoY. EBITDA Margin (%) came in at 12.7% PAT stood at Rs 171.6 crore as against Rs 166.4 crore YoY. PAT Margin (%) stood at 6.8% Commenting on the same, Adhish Patil, CFO & COO, Aarti Drugs said, “We are pleased with our financial and operational performance in FY24 amid geopolitical uncertainties and macroeconomic factors and price volatilities. The company demonstrated resilient performance in FY24, where topline declined by 7% YoY during full year FY24, attributed to lower realizations stemming from negative rate variance and subdued export market demand in APIs business. However, there has been a notable improvement in gross margins, credited to the stabilization of input costs in latter half of FY24 and operational efficiencies across the majority of our product lines. Furthermore, we anticipate a further enhancement in gross margins in future, mostly driven by upturn in selling price levels and an anticipated growth in export sales. EBITDA Margin for FY24 improved by ~140 basis points and PAT margins improved by ~70 basis points due to improved gross contributions in standalone as well as formulation business along with efficient working capital management. For Q4FY24, the company’s performance improved considerably on a sequential basis due to ease in the input costs and better product mix. On a sequential basis, the EBITDA margins improved by ~220 bps due to operating leverage driven by improved capacity utilization. Amidst heightened interest rates, dollar shortages, destocking, supply chain hurdles, and conservative ordering, export demand encountered challenges in select regions during Q4 and FY24. Nonetheless, we anticipate a positive shift in the export landscape in the near future, on back of interest rate reductions, low stock levels and an upswing in demand. Despite these hurdles, our outlook remains optimistic, on attaining our growth and margin targets. Formulation segment’s revenue stood at Rs 67.6 crore for the quarter, a growth of 19% YoY with exports contribution of ~62%. In FY24 revenues stood at Rs 324.6 crore, with growth of 18.5% YoY In the Specialty Chemical industry, although India's domestic chemicals demand is projected to remain robust in 2024, with low expectations in price increase. The market faces various challenges of finding equilibrium amidst the introduction of new production capacities within the country, shifting trade dynamics, subdued global demand, and fluctuating upstream prices. The company’s balance sheet continued to remain healthy with leverage remaining comfortably at 0.44x. The capex for FY24 stood at ~Rs. 226 crore. Recently, Greenfield project at Tarapur Facility for dermatology products has been commenced and the ramp up is planned throughout H1 FY25. Greenfield Project at Gujarat Sayakha for Speciality Chemicals is on track which we plan to commence by end of Q1 FY25. With this, the operating leverage is expected to kick in from H2 FY25 with improved capacity utilization. The company has incurred a capex of ~ Rs 543 crore in the last 3 years, mainly towards capacity expansion, backward integration and new product launches across API & Formulation segment. The majority of the company’s ? 600 crore capex has been completed and balance is expected to be completed soon. These initiatives are expected to reduce the costs along with expansion in the profit margins and the topline growth. The Pharma API manufacturing industry is constantly evolving, and we are committed to staying ahead of the curve. In the upcoming year, we plan to continue expanding our capabilities and enhancing our offerings to meet the ever-changing needs of our customers. One of our key goals for the upcoming year is to improve our capacity utilisation, allowing us to better serve our growing customer base. We also plan to invest in new technologies and equipment that will help us streamline our processes, reduce carbon footprint and improve efficiency.” Result PDF
06 May 2024

Aarti Drugs Results Earnings Call for Q4FY24

 Conference Call with Aarti Drugs Management and Analysts on Q4FY24 Performance and Outlook. Listen to the full earnings transcript.
Bigul
04 May 2024

AARTI DRUGS LTD. - 524348 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Intimation of Loss of share certificate.
See all News

FAQs

The latest market price of Aarti Drugs Ltd. on NSE was Rs. 490.00 as of today.

The opening share price of Aarti Drugs Ltd. was Rs. 487.50 as of today.

The 52-week high share price of Aarti Drugs Ltd. was Rs. 645.80.

The 52 week low share price of Aarti Drugs Ltd. was Rs. 431.00.

Aarti Drugs Ltd. has a market cap of Rs. 4504.80 crore as of today. Please refer to the Fundamentals section for further details.

The PE ratio of Aarti Drugs Ltd. is 8.60. Please refer to the Fundamentals section for further details.

The operating revenue for Aarti Drugs Ltd. in the last FY was Rs.  2528.58 crore. Please refer to the Financials section for further details.

The Net Profit for Aarti Drugs Ltd. in the last FY was Rs. 171.42 crore. Please refer to the Financials section for further details.

Please refer to Stock Ants, Bigul’s Community Access platform that aggregates tips and research from experts and provides real-time tracking to help investors validate, discover new investment ideas, and make informed decisions. Click here to learn more.

Please refer to Stock Ants, Bigul’s Community Access platform that aggregates tips and research from experts and provides real-time tracking to help investors validate, discover new investment ideas, and make informed decisions. Click here to learn more.

The latest dividend declared by Aarti Drugs Ltd. was on 2024-02-06 for Rs. 1 per share. According to today’s share price, the dividend yield of Aarti Drugs Ltd. stands at 0.20. Please refer to the Corporate Actions section for further details.

The latest bonus issue declared by Aarti Drugs Ltd. was as of 2020-09-30. The bonus ratio declared in this issue was 3:1. Please refer to the Corporate Actions section for further details.

Please find Corporate actions section for more details.

Please refer to Bigul Traders Corner, One Stop destination for different algo and non-algo trading strategies and tools meant for investors, traders, and strategists. Our qualified experts with rich experience in broking, financial analysis, and software development designed it in-house. Click here to learn more.

Please refer to JARVIS, which is Bigul’s AI Portfolio Manager Tool that uses artificial intelligence algorithms to make investment decisions in a portfolio. Click here to learn more.

Please refer to the News section for the latest news about Aarti Drugs Ltd..

Close

Let's Open Free Demat Account